GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valbiotis SA (XPAR:ALVAL) » Definitions » Loans Receivable

Valbiotis (XPAR:ALVAL) Loans Receivable : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Valbiotis Loans Receivable?

Valbiotis's Loans Receivable for the quarter that ended in Dec. 2023 was €0.00 Mil.


Valbiotis Loans Receivable Historical Data

The historical data trend for Valbiotis's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valbiotis Loans Receivable Chart

Valbiotis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only - - - - -

Valbiotis Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Valbiotis Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Valbiotis Loans Receivable Related Terms

Thank you for viewing the detailed overview of Valbiotis's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Valbiotis (XPAR:ALVAL) Business Description

Traded in Other Exchanges
Address
12F rue Paul VATINE, Perigny, La Rochelle, FRA, 17180
Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of major metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.

Valbiotis (XPAR:ALVAL) Headlines

No Headlines